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Ruchi Bansal 
 
AN INHIBITOR OF THE MITOTIC KINASE, MPS1, IS SELECTIVE TOWARDS 
PANCREATIC CANCER CELLS 
 
The abysmal five year pancreatic cancer survival rate of less than 6% highlights the need 
for new treatments for this deadly malignancy. Cytotoxic drugs normally target rapidly 
dividing cancer cells but unfortunately often target stem cells resulting in toxicity. This 
warrants the development of compounds that selectively target tumor cells. An inhibitor 
of the mitotic kinase, MPS1, which has been shown to be more selective towards cancer 
cells than non-tumorigenic cells, shows promise but its effects on stem cells has not been 
investigated. MPS1 is an essential component of the Spindle Assembly Checkpoint and is 
proposed to be up-regulated in cancer cells to maintain chromosomal segregation errors 
within survivable limits. Inhibition of MPS1 kinase causes cancer cell death accompanied 
by massive aneuploidy. Our studies demonstrate that human adipose stem cells (ASCs) 
and can tolerate higher levels of a small molecule MPS1 inhibitor than pancreatic cancer 
cells. In contrast to PANC-1 cancer cells, ASCs and telomerase-immortalized pancreatic 
ductal epithelial cells did not exhibit elevated chromosome mis-segregation after 
treatment with the MPS1 inhibitor for 72hrs. In contrast, PANC-1 pancreatic cancer cells 
exhibited a large increase in chromosomal mis-segregation under similar conditions. 
Furthermore, growth of ASCs was minimally affected post treatment whereas PANC-1 
cells were severely growth impaired suggesting a favorable therapeutic index. Our 
studies, demonstrate that MPS1 inhibition is selective towards pancreatic cancer cells and 
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that stem cells are less affected in vitro. These data suggest MPS1 inhibition should be 
further investigated as a new treatment approach in pancreatic cancer. 
 
Brenda R. Grimes, Ph.D., Chair 
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INTRODUCTION 
 
1. Mitosis 
 
Mitosis is the process of cell division of the somatic cells of eukaryotic organisms. The 
process is essential for the development, maintenance and regeneration of an individual. 
It is a part of the cell cycle which consists of four phases namely G1 (Gap1), S (DNA 
Synthesis), G2 (Gap2) and M (Mitosis) phase. Mitosis is divided in six stages such as 
prophase, prometaphase, metaphase, anaphase, telophase and cytokinesis. During 
prophase, the DNA is coiled and supercoiled to form compact genetic structures called 
chromosomes and the spindle apparatus begins to form followed by the disappearance of 
the nuclear membrane in prometaphase. Also, chromosomes are aligned at the metaphase 
plate, which is the cell’s equator, throughout metaphase after which the sister chromatids 
begin their journey to the opposite sides of the cell in anaphase. Cell division is 
completed with the process of cytokinesis where the mother cell is divided into two 
daughter cells. The mitotic spindle apparatus ensures that the daughter cells receive equal 
amount of DNA and it consists of the centrosomes, kinetochore, microtubules (MT) and 
microtubule associated proteins (MAPs) [Figure 1 adapted from (Bruce Alberts 2002)]. 
The centrosomes establish MT polarity and determine the number and distribution of 
microtubules. Each centrosome is composed of two centrioles, which are open-ended 
cylinders, each comprising of nine sets of triplet MTs linked together, plus some 
surrounding pericentriolar material. The kinetochore is a protein structure on chromatids 
where the spindle fibers attach during cell division to pull sister chromatids apart. The
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 Figure 1 Schematic representation of the spindle apparatus in metaphase 
Chromosomes are aligned at the metaphase plate. Microtubules arising from the 
centrosome attach to the kinetochores on each sister chromatid. The plus ends (growing 
ends) are away from the spindle poles. Spindle microtubules are classified into three 
categories: 
1. Astral microtubules that radiate in all directions, contribute to forces that separate the 
poles and are responsible for orientation and positioning of the spindle 
2. Kinetochore microtubules which attach to the kinetochore 
3. Overlap Microtubules that interdigitate at the equator of the spindle and are 
responsible for the symmetrical and bipolar shape of the spindle 
[Figure adapted from (Bruce Alberts 2002)] 
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kinetochore contains open chromatin but it assembles within a largely heterochromatic 
domain which is located on the centromere and is made of non-coding sequences called 
the repetitive alpha satellite DNA (Figure 2). The microtubules are the fundamental 
machinery of the spindle apparatus originating in the microtubule organizing center 
(MTOC), which is a part of the centrosome. These microtubules are hollow cylinders that 
are formed by the polymerization of a dimer of two globular proteins, alpha and beta 
tubulin and they form the spindle fibers that attach to the kinetochore and pull the sister 
chromatids away from each other towards the opposite ends of the cell. The attachment 
of the kinetochore and microtubules is governed by the spindle assembly checkpoint 
complex (SAC) which will be described in detail in later sections. Errors at any stage of 
the cell division lead to an abnormal number of chromosomes in daughter cells and/or 
structurally aberrant chromosomes causing genetic instability. 
 
2. Chromosomal Instability 
 
2.1.Definition of chromosomal instability 
 
Chromosomal instability (CIN), a form of genomic instability, is defined as an increased 
rate of change of number and/or structure of chromosomes. It was first defined by 
Vogelstein and his team in 1997 as ‘a striking defect in chromosome segregation, 
resulting in gains or losses in excess of 10–2 per chromosome per generation’ (Lengauer, 
Kinzler, and Vogelstein 1997). Since then, CIN has been shown to be promoted by many 
different mechanisms including defects in chromosome segregation, disturbances in the
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 Figure 2 Schematic representation of the organization of the kinetochore at the 
centromere 
The centromere consists of a higher order repeat of α-satellite DNA on which the 
kinetochore is built during mitosis. The sister chromatids are held together by cohesin 
complex until the end of metaphase. The inner kinetochore is marked with the epigenetic 
marker CENP-A, which is a variant of histone H3. The outer kinetochore is in contact 
with a kinesin motor protein called CENP-E and the proteins from the mitotic checkpoint 
complex also called the spindle assembly checkpoint (SAC). 
[Figure courtesy: Dr. Brenda Grimes] 
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cell cycle and faulty DNA damage repair systems (Thompson, Bakhoum, and Compton 
2010). Mutations in tumor suppressor genes such as p53 and RB also lead to cells 
becoming chromosomally unstable (Gordon, Resio, and Pellman 2012). Figure 3 
summarizes the four primary defects in mitosis that give rise to CIN namely, impaired 
SAC, defects in the geometry of the centromere, faulty attachments between the 
kinetochore and the microtubule and changes in the number of centrosomes in a cell 
[Figure 3 adapted from (Orr and Compton 2013)]. The activity or expression of the 
proteins that regulate these mechanisms are affected by mutations and changes in their 
upstream factors. For example, loss of function of the tumor suppressor gene RB disrupts 
the localization of cohesin proteins on the centromere thereby altering sister chromatid 
cohesion during cell division and causing CIN (Orr and Compton 2013, Manning, 
Longworth, and Dyson 2010). CIN and aneuploidy are interrelated, but both are 
distinguished from each other as CIN being the ‘rate of chromosomal mis-segregation’ 
and aneuploidy being the ‘state of abnormal chromosome number’ (Bakhoum and 
Compton 2012). 
 
CIN is classified into (1) numerical CIN (nCIN), which results in deviation of the normal 
chromosome number resulting in aneuploidy, and (2) structural CIN (sCIN), reflecting 
changes in the structure of the chromosome via mechanisms such as translocations, 
deletions, amplifications and inversions [Figure 4 adapted from (McGranahan et al. 
2012)]. nCIN is caused by different mechanisms such as errors in mitotic checkpoints, 
defects in the assembly of the spindle apparatus, defects in sister chromatid cohesion, 
amplification of centrosomes and faulty attachment of spindle microtubules to the  
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 Figure 3 Schematic representation of mitotic defects that cause CIN 
The innermost circle represents chromosomal instability (CIN). The middle circle 
comprises the four main defects in mitosis that are known to cause CIN while the 
outermost circle depicts the factors that regulate these mechanisms. These factors are the 
downstream targets for various oncogenic pathways shown in the bubbles. 
[Figure adapted from (Orr and Compton 2013)] 
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 Figure 4 Schematic representation of numerical and structural chromosomal 
instability 
Numerical chromosomal instability (nCIN) is characterized by gains and losses of whole 
chromosome(s) whereas structural chromosomal instability displays structural 
rearrangements such as translocations, deletions and amplifications within and between 
arms of chromosomes. 
[Figure adapted from (McGranahan et al. 2012)] 
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kinetochores (McGranahan et al. 2012). It is also reported that DNA damage occurs 
during aberrant chromosome segregation which can result in the subsequent structural 
rearrangement of chromosomes and contribute to sCIN (Janssen et al. 2011, Crasta et al. 
2012). sCIN is also reported to be associated with ‘reactive’ chromosomes which are 
formed after chromosome breaks. These reactive chromosomes give rise to ‘Breakage-
Fusion-Break’ cycles which in turn cause genomic rearrangements (Gisselsson et al. 
2000). Both nCIN and sCIN are often correlated with each other in cancer cells and result 
in a complex karyotype (Roschke et al. 2003, Gisselsson et al. 2000). 
 
CIN can have profound effects on the cell. The presence of CIN may lead to the 
formation of fusion gene products as well as deletion and amplification of genes making 
which in turn may propagate CIN further (McGranahan et al. 2012). Clinically, CIN 
causes congenital abnormalities, anatomic malfunctions and immunodeficiency in 
various instability syndromes such as Fanconi Anemia, Bloom Syndrome, Ataxia 
Telangiectasia and Roberts syndrome all of which have increased risks of developing 
malignancies (Zhang 2005). 
 
2.2.Measurement of chromosomal instability 
 
CIN needs to be characterized to measure the chromosomal variations between cells 
across a given population and also to assess the rate at which these variations change. 
Fluorescence in situ hybridization (FISH) has been used to assess CIN. An accepted 
method for indirectly inferring the nCIN using chromosome enumeration probes in FISH 
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analysis rate has been developed (Speicher and Carter 2005, Geigl et al. 2008, 
McGranahan et al. 2012). In this method, the nCIN rate is inferred by determining the 
percentage of cells exhibiting a chromosome signal number that deviates from the modal 
chromosome number. G-banding, FISH with regional/chromosome specific probes, 
spectral karyotype (SKY) analysis and Comparative Genomic Hybridization are 
cytogenetic methods for detecting sCIN. More recently, bioinformatics studies to detect 
changes in chromosome structure and number have been developed (McGranahan et al. 
2012, Carter et al. 2006). With the advent of next generation sequencing technology, it 
will be interesting to see how these tools will be exploited in determining CIN at the level 
of nucleotide sequence (McGranahan et al. 2012). 
 
2.3.Chromosomal instability in cancer: a benefit and a vulnerability 
 
CIN is a characteristic feature of most solid tumors and hematologic human cancers 
(McGranahan et al. 2012). It was first demonstrated in colorectal cancer cell lines by 
Vogelstein and his colleagues in 1997 (Lengauer, Kinzler, and Vogelstein 1997). CIN is 
associated with unfavorable prognosis in human cancer resulting in poor patient 
outcomes (McGranahan et al. 2012, Carter et al. 2006). CIN levels in tumors can stratify 
patients where high levels of CIN are generally linked to poorer survival and increased 
risk of relapse (McGranahan et al. 2012, Carter et al. 2006, Slee et al. 2014). 
 
CIN is proposed to be involved in the initiation and growth of tumors causing aneuploidy 
and intra-tumor heterogeneity (Bakhoum and Compton 2012, McGranahan et al. 2012). 
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Cancer cells that have elevated nCIN are reported to have elevated chromosomal mis-
segregation levels altering gene dosage and promoting Loss of Heterozygosity (LOH) 
events (Thompson and Compton 2008, Lengauer, Kinzler, and Vogelstein 1997, 
Bakhoum and Compton 2012). These genetic changes provide an advantage to cancer 
cells and allow them to tolerate and adapt to the stress present in the environment and 
facilitate emergence of drug resistant cells (McGranahan et al. 2012). However, this 
instability itself imposes stress and makes cancer cells potentially vulnerable (Gordon, 
Resio, and Pellman 2012). It may even play a role in tumor suppression if CIN gets too 
high by putting stress on the cells (Gordon, Resio, and Pellman 2012). 
 
CIN is reported to be a ‘double-edged sword’ where in addition to conferring tumor cells 
with selective advantages, it negatively impacts their biological fitness (Williams et al. 
2008). A threshold exists in the tolerance of CIN by cancer cells beyond which it is no 
longer compatible with cellular viability (Cahill et al. 1999). Elevated levels of 
chromosome segregation errors have been linked with DNA damage in the form of 
double strand breaks (DSBs) which lead to unbalanced translocations in daughter cells 
(Janssen et al. 2011). Daughter cells undergo cell death when the DSBs are not efficiently 
repaired or the gene imbalance as a result of the translocation is too severe for the cell 
(Janssen and Medema 2011). CIN results in the accumulation of deleterious mutations 
arising as a result of genomic rearrangement (Kops, Foltz, and Cleveland 2004, Janssen, 
Kops, and Medema 2009, Cahill et al. 1999). Earlier studies in yeast and mice have 
shown that the addition of an extra chromosome adds to the burden on the energy 
requirements of the cells because the genes on the extra chromosomes are being 
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replicated and transcribed slowing down cell growth and increasing cell lethality (Torres 
et al. 2007, Williams et al. 2008). It has been observed that cells make attempts to correct 
altered protein stoichiometry when chromosomally unstable (Tang et al. 2011). Pathways 
that stabilize normal cells under environmental stress are defective in tumor cells making 
them more vulnerable to stress inducing agents (Cahill et al. 1999). In a recent clinical 
study, extreme genomic instability in breast cancer was associated with favorable 
prognosis which might be explained by the vulnerable nature of cancer cells with an 
extremely high CIN level (Birkbak et al. 2011). Of interest to the hypothesis of this 
thesis, we test whether it is possible to selectively target CIN often seen in cancer cells to 
promote CIN elevation in them resulting in their death, while sparing normal cells. 
 
3. Mitotic kinase protein MPS1 as a potential therapeutic target 
 
3.1.Spindle Assembly Checkpoint Complex: 
 
Mitosis is a highly regulated process governed by the spindle assembly checkpoint (SAC) 
(also called Mitotic Checkpoint Complex (MCC)) to ensure legitimate segregation of 
chromosomes to the daughter cells. The role of the SAC, which is a large protein 
complex that binds to kinetochores, is to ensure proper alignment of the chromosomes at 
the metaphase plate and regulate bipolar attachment of the sister chromosomes to the 
mitotic spindle thus giving the green signal for the transition of the cells from metaphase 
to anaphase (Musacchio and Salmon 2007). 
 
 11   
 
Unattached and/or misaligned chromosomes signal the SAC to block the anaphase 
promoting complex (APC/C) by inactivating its activator cdc20 (Yu 2007, 2002). APC/C 
is an ubiquitin ligase that promotes the progression of mitosis from metaphase to 
anaphase. When the SAC is activated, it prevents the polyubiquitylation and proteasome 
mediated degradation of cyclin B and securin, both of which are bound to CDK1 and 
separase respectively arresting mitosis in prometaphase. On degradation of cyclin B, 
CDK1 is inactivated thereby promoting progression of mitosis whereas when securin is 
degraded, it releases separase which in turn cleaves the SCC1 component of the cohesin 
complex that binds the sister chromatids together. This event allows the sister chromatids 
to separate to opposite poles allowing anaphase to progress (Peters 2006). Figure 5 shows 
the key components and the functional mechanism of the SAC in the transition of 
prometaphase to anaphase [Figure 5 adapted from (Colombo and Moll 2010)]. 
 
3.2.Function of MPS1 kinase 
 
The SAC is a complex of proteins and one important component of this complex is 
monopolar spindle 1 (MPS1) kinase, also known as TTK (Colombo et al. 2010). MPS1 is 
a cell cycle regulated dual serine/threonine kinase and also phosphorylates tyrosine 
residues (Stucke et al. 2002). It is a highly dynamic kinase and is expressed only in 
proliferating cells with maximum activity during mitosis (Stucke et al. 2002, Colombo et 
al. 2010). The activity of MPS1 kinase increases with the activity of the SAC (Stucke et 
al. 2002). Though its exact functions remain unknown, MPS1 kinase is reported to be 
involved in the maintenance of the SAC as well as in stabilizing the attachment of the 
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 Figure 5 Key components and their function in Spindle Assembly Checkpoint 
Before metaphase, unattached chromatids trigger the Spindle Assembly checkpoint signal 
which comprises of BUB1, BUB3, MAD1, MAD2, MPS1 and BUBR1. This signal 
inhibits the APC/C by blocking cdc20. Once all the kinetochores are attached to the 
spindle microtubules, the SAC is released from kinetochores resulting in activation of 
APC/C. This in turn, degrades cyclin B and securin resulting the separation of sister 
chromatids and progression of the cell cycle into anaphase. 
[Figure adapted from (Colombo and Moll 2010)] 
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mitotic spindle fibers to the kinetochores (Janssen, Kops, and Medema 2009, Weiss and 
Winey 1996, Stucke et al. 2002). In addition, it localizes to the kinetochore and is 
required to recruit essential SAC proteins such as MAD1 and MAD2 to the kinetochore 
(Stucke et al. 2002, Liu et al. 2006, Tighe, Staples, and Taylor 2008, Kang et al. 2007). 
MPS1 inhibits post-mitotic checkpoint activation of the p53 signaling pathway in the 
event of controlled and normal chromosomal segregation (Tardif et al. 2011). In 
chromosomally unstable cancer cells, MPS1 kinase inhibition causes massive aneuploidy, 
which is incompatible with survival making it an excellent target in selective cancer 
therapeutics (Tighe, Staples, and Taylor 2008, Jelluma, Brenkman, van den Broek, et al. 
2008). Interestingly, normal fibroblasts and other differentiated cells are less affected 
thus creating a possible therapeutic window for treatment against a wide range of cancers 
(Colombo et al. 2010, Slee et al. 2014). 
 
3.3.Elevated Expression of MPS1 in chromosomally unstable cancer cells 
 
CIN is tolerated by cancer cells until a threshold is reached, beyond which it proves to be 
lethal to the cell. To maintain CIN within the survivable limits as well to reap the benefits 
provided by CIN, it is proposed that cancer cells up-regulate genes that are critical to 
limit chromosomal segregation errors (Grabsch et al. 2003, Schmidt and Medema 2006, 
Yuan et al. 2006). Carter and his group identified a set of 70 genes, called the CIN70 
signature, which in an unbiased bioinformatics approach turned out to stratify patients 
into groups based on survival or risk of relapse (Carter et al. 2006). In general, patients 
with high levels of CIN70 (which serves also as a surrogate measure of CIN) have a 
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poorer prognosis than those with lower CIN70 gene expression levels (Carter et al. 2006, 
Birkbak et al. 2011). CIN70 genes play a role in chromosome maintenance and include 3 
SAC genes. It is hypothesized that CIN70 gene up-regulation keeps CIN within limits to 
allow cancer cell survival. This increased reliance of tumor cells to elevate genes 
involved in chromosome maintenance is a form of “non-oncogene addiction” (Luo, 
Solimini, and Elledge 2009, Solimini, Luo, and Elledge 2007). Almost a quarter of these 
70 genes are associated with chromosomal segregation including MPS1 kinase (Carter et 
al. 2006, Luo, Solimini, and Elledge 2009). 
 
3.4.Inhibition of MPS1 as a therapeutic target in cancer cells 
 
MPS1 kinase activity is required in dividing cells for maintenance of the SAC and to 
ensure correct segregation of chromosomes. It is reported that inhibition of MPS1 kinase 
results in the override of the SAC and premature exit from mitosis (Schmidt et al. 2005, 
Kwiatkowski et al. 2010, Burgess, Rasouli, and Rogers 2014). Silencing of this mitotic 
kinase in mammalian cells has been shown to generate massive chromosomal mis-
segregation due to inaccurate alignment of chromosomes at the metaphase plate and 
accelerated mitosis ultimately leading to cell death (Tighe, Staples, and Taylor 2008, 
Jelluma, Brenkman, van den Broek, et al. 2008). Yeast cells that harbor mutations 
resulting in faulty chromosomal segregation are more sensitive to compounds that inhibit 
MPS1 kinase (Dorer et al. 2005). Many groups have demonstrated in a wide variety of 
tumor cell lines including cancer cells derived from lung, ovary and colon that targeted 
inhibition of MPS1 makes these cancer cells die via massive chromosome mis-
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segregation (Jemaa et al. 2012, Kwiatkowski et al. 2010, Castedo et al. 2004). The 
inhibition impairs SAC and kills human cancer cells by inducing hyperdiploidization, 
arresting growth and inhibiting DNA synthesis causing gross aneuploidy followed by cell 
death making MPS1 a potential therapeutic approach in cancer as normal cells are less 
affected (Jemaa et al. 2012, Tardif et al. 2011, Kwiatkowski et al. 2010, Slee et al. 2014, 
Colombo et al. 2010). 
 
One such MPS1 inhibitor [Figure 6 adapted from (Colombo et al. 2010)], NMS-P715, an 
ATP competitor was identified and characterized as a small-molecular inhibitor, which is 
selective towards cancer cell lines. NMS-P715 accelerates mitosis and affects localization 
of kinetochore components leading to massive aneuploidy and cell death leaving normal 
cells almost unaffected [Figure 7 adapted from (Colombo et al. 2010)]. The molecule is 
also shown to rapidly inhibit tumor growth in mouse xenograft models for ovarian 
carcinoma and malignant melanoma [Figure 8 adapted from (Colombo et al. 2010)]. 
 
4. Targeting pancreatic cancer cells 
 
Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer of the exocrine pancreas, a 
functional unit of the pancreas that produces digestive zymogens and forms 80% of the 
total tissue mass of the organ (Hezel et al. 2006). It is the most common form of 
pancreatic cancer and has an abysmal five year survival rate of less than 6% (Siegel, 
Naishadham, and Jemal 2012). It is the 4th highest contributor to cancer related deaths in 
the United States and there has been little improvement in patient survival over the last 
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 Figure 6 NMS-P715 is a selective ATP-competitor that inhibits MPS1 
NMS-P715 (shown in light blue competitively binds in the catalytic domain of MPS1 
kinase (shown as sticks with green carbon). Hydrogen bonds between NMS-P715 and 
MPS1 are represented by red dashed lines. 
[Figure adapted from (Colombo et al. 2010)] 
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 Figure 7 NMS-P715 inhibits Spindle Assembly Checkpoint affecting alignment of 
chromosomes and subsequently increases aneuploidy in treated cells 
A: Metaphase and anaphase images of U2OS osteosarcoma cell line that are treated with 
DMSO (control) or 1 µmol/L NMS- P715 for 1 hour. DNA is stained with DAPI (blue) 
while alpha-tubulin is visualized as green fluorescent signal YFP. 
B: Mitotic chromosome spread results of HCT116 colon cancer cells treated with NMS-
P715 (1 µmol/L) or DMSO (control) for 24 hours. Treated cells show a wide range of 
chromosome numbers/ cell consistent with increased aneuploidy after treatment with the 
inhibitor. 
[Figure adapted from (Colombo et al. 2010)] 
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 Figure 8 NMS-P715 inhibits growth of tumors in xenograft models 
A: Nude mice bearing xenograft derived ovarian cancer tumors (A2780human cell line) 
show a significant reduction of tumor weight after oral administration of 90mg/kg NMS-
P715 (gray bar) daily for 7 consecutive days when compared to the control group. 
B: A375 human melanoma xenograft model also showed significant decrease in tumor 
weight after they were orally administered with 100mg/kg NMS-P715 for 2 consecutive 
days over a 10 day period as compared to the control group. 
[Figure adapted from (Colombo et al. 2010)] 
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30 years (Siegel, Naishadham, and Jemal 2012). Pancreatic cancer is typically detected at 
a later stage as the disease is symptom-free in the early stages and has a high metastatic 
propensity making surgery and other therapeutic interventions inadequate (Karhu, 
Mahlamaki, and Kallioniemi 2006). The current compound used in PDAC treatment, the 
DNA synthesis inhibitor gemcitabine, does little to improve the overall survival (Choi, 
Saif, and Kim 2014). This stresses the need to develop new therapeutic options that 
improve survival of patients suffering from PDAC. 
 
PDAC tumor cells are genetically very complex, show extensive heterogeneity, and are 
highly unstable leading to acquired clonal aberrations and complex karyotypes (Karhu, 
Mahlamaki, and Kallioniemi 2006, Gorunova et al. 1998). The most common mutation 
that is observed in over 90% of PDAC tumors is the activating mutation of KRAS 
oncogene (Hansel, Kern, and Hruban 2003). Elevated CIN70 gene expression, including 
that of MPS1 kinase, in PDAC patient tumor samples indicated poor prognosis (Slee et 
al. 2014). Patients with PDAC were categorized into prognostic categories based on their 
MPS1 kinase expression levels [Figure 9 adapted from (Slee et al. 2014)]. In addition, 
MPS1 kinase was highly expressed in PDAC cell lines such as BxPC3 and PANC-1 in 
comparison with primary pancreatic ductal epithelial cells [Figure 10 adapted from (Slee 
et al. 2014)]. Due to the presence of CIN and elevated MPS1 kinase levels, we explored 
the potential of NMS-P715 to 1) inhibit PDAC cell growth and 2) have less effect on 
stem cells, as these cells are the main target of cytotoxic compounds widely used in 
chemotherapy. 
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 Figure 9 Kaplan-Meier Survival analyses of 94 PDAC patients segregated by level of 
MPS1 expression 
The graph represents the survival analysis of 94 PDAC patients relative to levels of 
MPS1 expression. The patients were classified in two prognostic categories namely the 
‘upper’ and ‘lower’ halves based on the expression of MPS1. The median survival for 
upper half patients is 28 months whereas that for the lower half is 13.2 months. 
[Figure adapted from (Slee et al. 2014)] 
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Figure 10 MPS1 is up-regulated in pancreatic cancer 
A: Box whisker plot of MPS1 expression in normal pancreatic cells and PDAC cells. 
Central band indicates the median and the lower and upper bands denote first and the 
third quartiles respectively. Whiskers represent the data within the 1.5 interquartiles of 
upper and lower box limits. Red bars indicate outliers. 
B: MPS1 gene expression in primary human pancreatic ductal epithelial cells (hPDEC), 
BxPC-3, and PANC-1 cell lines. 
[Figure adapted from (Slee et al. 2014)] 
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5. Human Adipose Stem Cells 
 
Therapeutic Index is defined as the ratio of the concentration of the drug required for the 
toxic effects to the concentration required for therapeutic effects (Kaelin 2005). A drug is 
reported to have a favorable therapeutic index when it targets a biomolecule that is 
important for the survival of a cancer cell without compromising normal cellular survival 
or function (Rubin and Gilliland 2012). Most of the chemotherapeutic compounds in use 
today, including gemcitabine, have very low therapeutic indices as they damage normal 
cells such as the stem cells of the bone marrow and the normal epithelia of the gut 
(Kaelin 2005). As a result, the success rate of most anticancer drugs remains low (Rubin 
and Gilliland 2012). NMS-P715 is shown to have a favorable therapeutic index in 
untransformed cells such as fibroblasts and B-lymphocytes as they are almost unaffected 
by it under conditions where cancer cells are severely affected (Colombo et al. 2010). 
Since NMS-P715 was not tested in stem cells, we wanted to check whether it inhibited 
MPS1 kinase in adipose derived mesenchymal stem cells (ASCs) as a model for how 
stem cells might be affected in vivo. 
 
ASCs are multipotent stem cells that were isolated from donors who underwent 
liposuction procedures. They share many properties with the bone marrow derived 
mesenchymal stem cells (Hong, Traktuev, and March 2010). These cells have high 
proliferation capacity in vitro and maintain a stable diploid karyotype (Grimes et al. 
2009). As gemcitabine affects stem cells in vivo, the relative sensitivities of pancreatic 
cancer cells and ASCs to both Gemcitabine and NMS-P715 were analyzed by Dr. Roger 
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B. Slee from Grimes’ Lab. Pancreatic cancer cell lines such as PANC-1 and BxPC-3 
were significantly more sensitive to the inhibitory effects of NMS-P715 than five isolates 
of ASCs when treated with increasing concentrations of the drug for 72 hours [Figures 11 
A and 11B adapted from (Slee et al. 2014)]. This was also reflected in the IC50 values 
which were 1.5, 1.6 and 3.4 µmol/L for PANC-1, BxPC-3 and ASCs respectively [Figure 
11C adapted from (Slee et al. 2014)]. These results when compared to those observed in 
the PDAC cells were more resistant than ASCs suggesting a favorable therapeutic index 
for the MPS1 kinase inhibitor (Slee et al. 2014). Based on the results established in the 
previous studies and Dr. Slee’s experiments, we hypothesize that MPS1 inhibition is 
selective towards PDAC cells and that stem cells will be more resistant in vitro. In 
addition, we also tested whether normal human pancreatic ductal epithelial (hTERT-
HPNE) cells immortalized by human telomerase, were negatively affected by the 
inhibition of MPS1 kinase. The inhibitor was tested in murine PDAC cells (Carriere et al. 
2011). The results presented in this thesis focus on the relative resistance of stem cells 
and normal pancreatic epithelial cells to the NMS-P715 inhibitor of MPS1 kinase 
compared to pancreatic cancer cells and support further testing of MPS1 inhibitors as 
potential selective agents for treatment of pancreatic cancer. 
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 Figure 11 Sensitivities of Pancreatic Cancer Cells and ASCs to both gemcitabine 
and NMS-P715 
A: IC50 values of NMS-P715 in BxPC-3, PANC-1 and ASC 
B: IC50 valued of gemcitabine in BxPC-3, PANC-1 and ASC 
C: PANC-1 and BxPC-3 are more sensitive to the inhibitory effects of NMS-P715 than 
ASCs 
[Figure adapted from (Slee et al. 2014)] 
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MATERIALS AND METHODS 
 
1. Cell lines 
 
Human PDAC cell lines PANC-1 (ATCC CRL-1469) and BxPC-3 (ATCC CRL-1687) 
were grown in Dulbecco’s Modified Eagle Medium/10% FBS or RPMI/10% FBS, 
respectively, obtained from American Type Culture Collection (ATCC). 825-2 and 1170-
4 KRC cells are murine PDAC cells that were obtained from two pancreatic cancer 
tumors arising in a genetically engineered mouse model of PDAC in which Kras was 
combined with Rb (Retinoblastoma) gene deletion using Cre-recombinase (Carriere et al. 
2011) and were cultured in RPMI/10% FBS. Human ASCs were collected from donors 
undergoing lipoaspiration using an approved protocol (Institutional Review Board 0305-
59) as described previously (Hong, Traktuev, and March 2010) and cultured in EGM2-
MV medium (Lonza)/ 10% FBS. Human telomerase-immortalized pancreatic ductal 
epithelial cells (hTERT-HPNE) cells (ATCC CRL-4023) were cultured according to the 
supplier’s conditions. The cells were maintained in a humidified atmosphere of 5%CO2 
at 37°C. 
 
The population doubling times of PANC-1, BxPC-3, KRC, ASC and hTERT-HPNE cells 
were approximately 50 hours, 40 to 60 hours, 20 hours, 24 to 26 hours and 40 hours 
respectively. 
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2. Compounds 
 
NMS-P715 was provided by Nerviano Medical Sciences or purchased from EMD 
Millipore (Cat#475949-5MG) and suspended in dimethyl sulphoxide (DMSO). 
Gemcitabine, obtained from Tocris Bioscience, was suspended in H2O. 
 
3. Clonogenic Survival Assay 
 
Cells were counted and plated in duplicate or triplicate in 12 well dishes. The inhibitor 
was added after 24 hours at concentrations ranging from 0.1 to 5.0 µmol/L. DMSO was 
used as a control. For continuous treatment, the inhibitor was added every 3 days whereas 
in washout condition the cells were treated with the inhibitor for 24 hours and then grown 
in compound-free medium. The total duration of cell growth was 9 days or 6 days after 
the first addition of the drug. Cells were fixed with methanol for 15 minutes and left to 
dry overnight. The plates were then stained with 0.05% methylene blue (w/v) for 15 
minutes, rinsed twice in water and dried overnight. Cell growth was quantified by 
suspending cells in 0.5 mol/L hydrochloric acid and the optical density was measured at 
320 nM on a Beckman-Coulter DTX880 MultiMode Detector (Oliver et al. 1989). 
Inhibition of growth by NMS-P715 was measured relative to the DMSO control. 
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4. SAC Override analysis by Immunoblotting Assay 
 
4.1.Preparation of Cell Lysate 
 
Cells were treated with increasing concentrations of NMS-P715 or DMSO control for 72 
hours after which, media was aspirated from cultures. Then cells were harvested by 
adding 1ml 0.25% Trypsin (Thermo Scientific) and collected in graduated 15 ml 
centrifuge tubes (Sarstedt). The cells were washed with 1X PBS (Dulbecco), counted 
using Beckman Coulter Counter and frozen at -80°C overnight in medium supplemented 
with 10% DMSO until next use. After thawing the cells on ice, the cells were lysed by 
resuspension in RIPA buffer (Thermo Scientific) and sonication for 30 seconds at 10 
second intervals to shear DNA and reduce viscosity. A 15µl aliquot removed then 15µl 
RIPA buffer, 15µl 3X Loading Buffer and 1µl 2-Mercaptoethanol (BME) were added 
then the sample was heated for 3 minutes at 90°C followed by cooling on ice. 
 
4.2.SDS-polyacrylamide gel electrophoresis of protein and transfer: 
 
30µl of sample was loaded onto SDS-PAGE gel (10cm X 8.5cm) (Thermo Scientific) and 
electrophoresis was performed. After separation on the gel, proteins were electroblotted 
onto Polyvinylidene fluoride (PVDF) membrane (Biorad) overnight at 30V at 4°C. The 
transfer buffer contained 30mM Tris, 200mM glycine, 1.4mM SDS and 20% methanol. 
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4.3.Immunoblotting 
 
The membranes were incubated while under constant agitation in blocking buffer [3% 
(w/v) non-fat dry milk in PBS] at room temperature for 1 hour. After washing briefly in 
1XPBS-T buffer (1X PBS / 0.05% Tween), membranes were immunoblotted in blocking 
buffer containing primary antibody [phosphorylated histone H3 serine 10 (pS10H3); 
(Millipore)] at a concentration of 1:1000 (v/v) at room temperature for 2 hours. 
Membranes were washed 3 times, each wash for 10 minutes, with 1XPBS-T buffer, 
followed by incubation in blocking buffer containing goat-anti-rabbit-horseradish-
peroxidase conjugates [1:5000 (v/v)] for 1 hour at room temperature. After three washes 
(10 minutes each wash) in 1XPBS-T buffer, the membranes were exposed to enhanced 
chemilumescent (ECL) plus mixture (Thermo Scientific Pierce) for 1 minute, and 
exposed to autoradiographic film from 10 seconds to 5 minutes to obtain desired signal 
intensity. The same procedure was followed for a loading control using β-Actin (Sigma) 
[1:10000 (v/v)] as the primary antibody and goat-anti-mouse-horse radish peroxidase 
conjugate [1:5000 (v/v)] as the detecting antibody. 
 
5. SAC Override Assay by Immunofluorescence 
 
5.1.Cell Fixation 
 
PANC-1 and BxPC-3 Cells were counted and plated in chamber slides at a concentration 
of 10,000 to 20,000 cells/well. After 24 hours, replicate cultures were blocked in 
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75nmol/M nocodazole for 18 hours. The cells were treated either with DMSO or 0.4 
µmol/L NMS-P715 in the last two hours of block. Murine PDAC cells were plated at 
same densities as that of human PDAC cells but were treated with increasing 
concentration of nocodazole for 18 hours without NMS-P715 treatment. DMSO was used 
as control. The cells were then fixed in 1XPBS/4% formaldehyde for 15 minutes at room 
temperature and washed three times in 1XPBS for 5 minutes each. 
 
5.2.Immunofluorescence 
 
The cells were blocked for 60 minutes in 100 µl of blocking buffer containing 1X PBS, 
5% normal goat serum and 0.3% Triton X-100. The cells were then incubated overnight 
at 4°C with Alexa-Fluor 488-labeled pS10H3 antibody (Cell Signaling Technologies) 
which was diluted in the antibody dilution buffer (1x PBS/ 1% bovine serum albumin 
(BSA)/ 0.3% Triton X-100) in a dark moist chamber. After incubation, the cells were 
rinsed thoroughly with PBS three times for 5 minutes each at room temperature. The 
nuclei were counterstained with 6-diamidino-2-phenylindole (DAPI) and observed under 
a Leica DM5000B fluorescence microscope (Leica Microsystems). A minimum of 200 
cells per well were scored for the presence of green pS10H3 positive cells. The assay was 
performed in duplicates. 
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6. Measuring nCIN using Fluorescence In Situ Hybridization 
 
6.1.Cell Fixation 
 
Duplicate cell cultures were incubated with NMS-P715 or DMSO control for 72 hours 
after which they were harvested using 1 ml 0.25% Trypsin/EDTA) and centrifuged at 
1000 rpm for 5 minutes. The cells were incubated for 10 minutes at 37°C in hypotonic 
buffer (0.075M KCl). The cells were then fixed in 3:1 (v/v) methanol: acetic acid, 
dropped on slides and aged under vacuum overnight. 
 
6.2.Preparation of FISH probes 
 
Commercial probes recognizing X chromosome or chromosome 17 centromeres (Abbott 
Molecular Cat# 05-J08-033, 06-J37-027 respectively) in human cells were aliquoted into 
hybrisol containing 50%formamide, 20%dextran sulfate, 2XSSC and 0.1mg/ml salmon 
sperm DNA. The probes were denatured at 72°C for 7 minutes, and then placed on ice in 
dark. 
 
For murine cells, commercial probe for mouse chromosome 11qE1 (Kreatech 
Diagnostics Cat#30501) was aliquoted in mouse probe solution containing ultrapure 
deionized water and large-scale integration (LSI) hybridization buffer provided by the 
supplier. The probe was denatured at 73°C for 5 minutes and placed on ice in dark prior 
to adding to slides. 
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6.3.Hybridization 
 
The slides containing the cells were preheated in 2X SSC at 37°C for approximately 30 
minutes. The slides were washed three times in 70%, 80% and 100% ethanol sequentially 
for 2 minutes each at -20°C and dried at room temperature. The slides were placed in 
denature solution (70%Formamide/2XSSC; pH 7.0) for 2 minutes at 72°C to denature 
DNA. The cells were again sequentially washed with ethanol at -20°C and dried at room 
temperature. 15µl of the human probe mixture or 10µl of the mouse probe was added to 
the samples and sealed in a coverslip. The slides were incubated overnight in a moist 
chamber at 37°C. 
 
After incubation, the PDAC and ASC slides were placed twice in post hybridization wash 
solution (50%Formamide/2XSSC; pH 7.0) at 42°C for 8 minutes each followed by a 
wash in 2XSSC at 37°C for 8 minutes. KRC slides were placed in post hybridization 
wash I (0.4X SSC/0.3%NP40) at 73°C for 2 minutes followed by wash in post 
hybridization wash II solution (2X SSC/ 0.1%NP40) at room temperature for 1 minute. 
 
The nuclei were counterstained with 6-diamidino-2-phenylindole (DAPI) and observed 
under Leica DM5000B fluorescence microscope (Leica Microsystems). Chromosome 
numbers were counted in ≥50 spreads per culture. 
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RESULTS 
 
1. Pancreatic cancer cell growth is selectively inhibited by MPS1 inhibitor NMS-
P715 whereas human stem cells are markedly less affected. 
 
To examine the specificity of MPS1 inhibition by NMS-P715, we tested and compared 
the effects of the drug in pancreatic cancer cells with that in the normal adipose stem cells 
(ASCs) using a clonogenic survival assay. The assay assesses the ability of the cells to 
divide and proliferate after an external insult to them (Puck and Marcus 1956). This long 
term assay is an indirect measurement of cell death in vitro where it takes into account 
the different mechanisms that kill cancer cells (Brown and Attardi 2005). This is 
observed as a decrease in the cell number after the treatment under consideration. To 
analyze the growth inhibitory effects of the drug, we checked for the proliferative 
capacity of the cells after treatment with NMS-P715. The assay requires the formation of 
large, deeply staining colonies each consisting of more than 50 cells as an indicator that 
the cells have retained their clonogenic properties (Puck and Marcus 1956). Hence, the 
optimum seeding number and length of treatment is different for each cell line and 
experiment to obtain the best representative results in the clonogenic survival assay. 
 
PANC-1 and BxPC-3 cells were seeded at concentrations of 500 and 1000 cells/well 
respectively. When PDAC cells were treated continuously for 9 days with NMS-P715 at 
concentrations ranging from 0.1 µmol/L to 5.0 µmol/L, their growth was markedly 
inhibited at 0.5 µmol/L (Figure 12A). In addition, a treatment of 1.0 µmol/L NMS-P715 
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for 24 hours followed by compound washout significantly reduced the proliferation of 
PANC-1 and BxPC-3 indicating high sensitivity to the drug (Figure 12A). On the other 
hand, ASCs were more resistant when they were plated at a density of 200 cells/well and 
treated with the drug for 6 days continuously at increasing concentrations from 0.1 
µmol/L to 5 µmol/L (Figure 12B). The stem cells show a marginal decrease in cell 
growth at 0.5 µmol/L when compared to that in 0.1 µmol/L but are still actively 
proliferating which is in contrast to that observed in PDAC cells. 
 
However since ASCs do not form colonies at low plating numbers because they are 
migratory (Figure 12B), cell growth was measured using an indirect colorimetric assay to 
quantitatively compare the growth of PDAC cells with ASCs after MPS1 inhibition. In 
this assay, cells were fixed and stained with methylene blue. The dye was released by 
lowering the pH with hydrochloric acid and the intensity of the color of the extracted dye 
was measured as the absorbance on a plate reader (Oliver et al. 1989). PANC-1, BxPC-3 
and ASC were plated at a density of 200cells/well and treated with NMS-P715 at 
concentrations varying from 0.1 µmol/L to 0.5 µmol/L for 6 days. A clear trend is visible 
where the number of cells surviving after treatment decreases with the increasing 
concentration of the drug (Figure 12 C). The percentage of PDAC cells surviving 
decreases sharply in comparison with that of the ASCs. Also, the PDAC cells seem to be 
more sensitive than the ASCs to MPS1 inhibition and there is significant difference 
between their survivals when treated with 0.3 µmol/L, 0.4 µmol/L and 0.5 µmol/L NMS-
P715. In addition, the growth inhibition of PANC-1 (75.1% ± 7.7%) and BxPC-3 
(78.83% ± 4.49%) was twice that observed in the ASCs (38.2% ± 8.5%). These data are 
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 Figure 12 NMS-P715 selectively inhibits cancer cell proliferation leaving ASCs 
relatively unaffected 
A: Growth inhibition of PANC-1 and BxPC-3 cells plated at concentrations of 500 and 
1000cells/well respectively when treated with NMS-P715 for 9 days continuously or for 
24 hours followed by growth in compound-free medium for 9 days (washout treatment). 
B: Cell proliferation of two independent ASC1 and ASC2 isolates treated with NMS-
P715 for 6 days continuously. The cells were seeded at concentration of 200cells/well. 
C: Comparison of clonogenic effect in BxPC-3, PANC-1 and ASC after treatment with 
NMS-P715 for 6 days continuously using colorimetric analysis. The cells were plated at a 
density of 200cells/well. 
The assays were performed in duplicates.  
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published in (Slee et al. 2014). 
 
To permit additional assessment of the anti-proliferative effects of the MPS1 inhibitor, 
PANC-1 cells and ASCs were first treated with 1.0 µmol/L NMS-P715 for 72 hours in a 
different clonogenic survival assay. DMSO was used as control. Cells were harvested and 
plated at 400 cells/well in compound-free medium in a 12 well dish for 6 days. PANC-1 
cells showed significantly higher growth inhibition (72.2%) than that observed in ASC3 
(16.1%) and ASC4 (23.2%) (Figure 13) (Slee et al. 2014). 
 
2. Pancreatic cancer cells bypass the mitotic checkpoint after treatment with NMS-
P715. 
 
The spindle assembly checkpoint (SAC) is an essential regulator of mitotic cell division 
where it acts as a gatekeeper during the transition of the cell from metaphase to anaphase 
thus keeping chromosome segregation under check (Musacchio and Salmon 2007). It 
delays the onset of anaphase until all kinetochores are properly attached to the spindle 
microtubules (Schmidt et al. 2005). Defects in this protein complex abrogate the 
checkpoint mechanism causing premature transition in anaphase (Thompson and 
Compton 2008). It has been previously shown that cells having a weak SAC show 
chromosomal instability (CIN) and undergo mitotic catastrophe (Burds, Lutum, and 
Sorger 2005). With this rationale, we wanted to assess whether MPS1 inhibition makes 
PDAC cells override the SAC, by testing the presence of phosphorylation at serine 10 on 
histone H3 (pS10H3). This histone modification is associated with chromosome 
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 Figure 13 PDAC cell growth is inhibited by pre-treatment with 1µM NMS-P715 for 
72 hours while human adipose stem cells are markedly less affected 
A: Image showing PANC-1 and ASCs were pre-treated with 1µmol/L P715 for 72 hours 
before being plated at densities of 400cells/well in triplicate in compound free medium 
for 6 days. DMSO was used as control. Cells in columns 1 and 2 are controls while those 
in 3 and 4 are treated with the inhibitor. 
B: Graph showing percent growth inhibition of PANC-1 and ASCs relative to control 
group after treatment with 1µmol/L P715 for 72 hours NMS-P715 determined by 
colorimetric assay. The growth of ASCs is almost three times more than PANC-1 after 
treatment with the inhibitor.  
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condensation during mitosis (Hendzel et al. 1997, Prigent and Dimitrov 2003). 
Phosphorylation at Ser 10 begins in late G2 phase and reaches its maximum at 
metaphase. Dephosphorylation begins in anaphase and ends in telophase indicating 
decondensation of chromosomes (Hendzel et al. 1997). Thus, disappearance of pS10H3 
indicates that cells have passed through mitosis (Kwiatkowski et al. 2010) and we tested 
the absence of this marker in PANC-1 cells after treatment with NMS-P715. In addition, 
we repeated this experiment in ASCs to compare the effect on SAC in PANC-1 with that 
observed in the stem cells. 
 
Cells were treated with increasing concentration of MPS1 inhibitor for 72 hours. The 
PANC-1 cells showed dose-dependent reduction of pS10H3 using Western analysis, 
suggesting early exit from mitosis and hence, bypassing the SAC. On the other hand, 
ASCs did not show a decrease in pS10H3 marker when treated with the same conditions 
(Figure 14). 
 
To confirm the failure of SAC to arrest in PDAC cells, the cells were treated with NMS-
P715 in the presence of nocodazole, a microtubule depolymerizing agent. Addition of 
nocodazole to dividing cells prevents the microtubules from attaching to the kinetochore 
which results in the activation of the SAC (Stucke et al. 2002). 
 
However, cells with a weakened checkpoint will fail to arrest in prometaphase in the 
event of unattached kinetochores and transition into anaphase (Jelluma, Brenkman, 
McLeod, et al. 2008). To check the ability of NMS-P715 to cause the bypass of the 
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 Figure 14 PANC-1 cells exhibit bypass of the SAC in the presence of NMS-P715, in 
contrast to ASCs which maintained an intact SAC under similar treatment 
conditions 
Image showing western blot analysis of PANC-1 cells and ASCs when treated with the 
indicated concentrations of NMS-P715. ‘0’ indicates DMSO control. Antibody to 
pS10H3 detected cells in mitosis while antibody to β-actin was used as control. 
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checkpoint, we tested the inhibitor in PANC-1 and BxPC-3 cells after activating the 
checkpoint signaling with nocodazole and scored the frequency of pS10H3 positive 
nuclei. Cells were blocked in 75nmol/L nocodazole for 18 hours and were treated with 
0.4 µmol/L NMS-P715 in the last two hours of the nocodazole treatment. Both PANC-1 
and BxPC-3 showed a significant decrease in pS10H3 positive nuclei after treatment with 
the MPS1 inhibitor (Figure 15). The reduction in the number of cells arrested in 
prometaphase indicates that the depletion of MPS1 in the cells caused the checkpoint to 
become dysfunctional resulting the cells to exit mitosis prematurely. The experiment was 
attempted in the ASCs. However ASCs did not grow uniformly making analysis and 
interpretation ambiguous. Thus we relied on results from Western analysis to measure 
comparative resistance to SAC override in ASCs as outlined above. 
 
These results suggest that NMS-P715 abrogates the function of the SAC in PANC-1 cells 
and that ASCs are resistant to this weakening of the checkpoint when treated with same 
concentration of the inhibitor, thereby lending support to the possibility that the inhibitor 
is more selective to cancer cells than stem cells. 
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 Figure 15 PDAC cells fail to arrest in prometaphase after treatment with nocodazole 
in the presence of NMS-P715 and exit mitosis prematurely 
On the left is the graph showing the percentage of pS10H3 positive green cells when 
treated with nocodazole (noc) only or with nocodazole and NMS-P715 (noc + NMS-
P715). A minimum of 200 cells per chamber were scored for the presence of green cells 
indicating the presence of pS10H3. On the right are representative images of cells when 
treated with noc or noc + NMS-P715. Nuclei are stained with DAPI (blue). The assay 
was performed in duplicate. 
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3. Pancreatic cancer cells are more chromosomally unstable than normal healthy 
cells after treatment with NMS-P715. 
 
A decrease in the activity of MPS1 abrogates the functioning of the SAC (Jelluma, 
Brenkman, McLeod, et al. 2008) and increases errors in chromosomal segregation 
thereby promoting catastrophic CIN (Kops, Foltz, and Cleveland 2004, Colombo and 
Moll 2010). In addition, elevation of CIN beyond a threshold is not tolerated by cancer 
cells and they succumb to the deleterious effects of this phenotype (Cahill et al. 1999, 
Kops, Foltz, and Cleveland 2004) making CIN elevation an attractive therapeutic target 
in the treatment of many cancers (Colombo et al. 2010). With this rationale, we wanted to 
test for increased levels of numerical CIN in PDAC after treatment with the MPS1 
inhibitor. We also wanted to check whether ASCs and hTERT-HPNE were resistant to 
increase in nCIN under conditions similar to that in PANC-1, suggesting a therapeutic 
window exists allowing selective targeting of cancer cells. To explore this hypothesis, we 
performed fluorescence in situ hybridization (FISH) to examine levels of nCIN after 
treating the cells with 1 µmol/L NMS-P715 or DMSO for 72 hours by assessing changes 
in percent modal deviation (%MD) for chromosome enumeration probes after treatment 
which is an accepted indirect measure of the CIN rate. %MD was calculated for 
chromosomes X and 17. As the alpha satellite DNA is divergent between centromeres in 
humans, probes were specific to chromosomes X and 17 (Willard 1985). 
 
PANC-1 showed significantly elevated levels of nCIN as compared to ASCs prior to 
treatment, consistent with the chromosomally unstable phenotype of cancer cells (Figure 
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16). PANC-1 showed a dramatic increase in nCIN from 13% MD for chromosome X and 
14% MD for chromosome 17 when treated with DMSO to 63% MD for chromosome X 
and 59% for chromosome 17 after treatment with 1 µmol/L inhibitor for 72 hours. On the 
other hand, the %MD in ASCs was less than 5% in both control and test samples making 
the change after treatment with NMS-P715 statistically insignificant suggesting that the 
chromosome mis-segregation rate was similar in treated or control conditions. To 
understand the limit to which the ASCs can tolerate the drug, we treated the cells with 3 
µmol/L NMS-P715 for 72 hours and observed a significant, but modest increase in %MD 
from less than 5% for chromosomes X and 17 in control to 20% for chromosome X and 
17% for chromosome 17 after treatment with the higher concentration of the drug. 
 
In addition, normal pancreatic epithelial cells (hTERT-HPNE), which are telomerase-
immortalized, showed a small but statistically insignificant increase in nCIN after 
treatment with 1 µmol/L NMS-P715 for 72 hours providing further supporting evidence 
that untransformed cells are less susceptible to SAC over-ride using an MPS1 inhibitor 
(Figure 17). On the contrary, a statistically significant increase in nCIN was observed in 
PANC-1 cells when they were treated under similar conditions as hTERT-HPNE. 
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 Figure 16 MPS1 inhibition elevates nCIN in PANC-1 cells but not in ASCs 
PANC-1 and ASCs were treated with 1 µmol/L NMS-P715 for 72 hours and processed 
for FISH. ≥50 cells per culture were analyzed for the number of chromosomes. Green 
probe represents chromosome 17 whereas red indicates chromosome X. The modal 
number for chromosomes 17 and X was 4 for PANC-1 and 2 for ASCs. PANC-1 cells 
show significant elevation in CIN after treatment with the inhibitor. Although ASCs are 
resistant to the inhibition of MPS1 under conditions similar to that for PANC-1, the stem 
cells show significant but modest increase when treated with higher concentration (3 
µmol/L) of the drug. The assay was performed in 2 replicate plates per treatment group. 
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 Figure 17 hTERT-HPNE cells are resistant to elevation of nCIN when treated with 1 
µmol/L NMS-P715 for 72 hours 
PANC-1 and hTERT-HPNE cells were treated with 1 µmol/L NMS-P715 or DMSO for 
72 hours and processed for FISH analysis. A minimum of 50 interphase cells per culture 
were scored for number of chromosomes X and 17. hTERT-HPNE show slight but 
statistically insignificant increase in percent modal deviation whereas PANC-1 show a 
dramatic increase in %MD for both chromosomes X and 17, indicating higher sensitivity 
towards NMS-P715 than that observed in hTERT-HPNE under similar conditions. The 
assay was performed in 2 replicates per treatment group. 
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4. Growth of murine PDAC cells is inhibited by NMS-P715 
 
To assess the effect of MPS1 inhibition in murine PDAC cells, 825-2 and 1170-4 KRC 
cells were checked for their clonogenic capacity after treatment with NMS-P715. KRC 
cells were derived from PDAC tumors arising from genetically engineered mice with 
oncogenic Kras and deletion of the retinoblastoma (Rb) gene using Cre-recombinase 
(Carriere et al. 2011). 825-2 and 1170-4 KRC cells were plated at a density of 100 and 50 
cells/well respectively and were treated with NMS-P715 at concentrations ranging from 
0.3 µmol/L to 1.0 µmol/L for 5 days continuously or for 24 hours followed by growth for 
4 days in the absence of the inhibitor (washout treatment). DMSO was used as vehicle 
control. Large colonies with ≥50 cells that were stained with giemsa were scored. There 
is dose depended decrease in the growth of KRC cells after inhibition of MPS1. In the 
continuous treatment with the drug, the growth of 825-2 and 1170-4 cells was completely 
inhibited at drug concentrations from 0.5-0.7 µmol/L and 0.7-0.9 µmol/L respectively 
whereas in the washout experiment the growth of the KRC cells decreased by 85% when 
treated with 1.0 µmol/L for 24 hours (Figure 18A) suggesting a very potent effect on 
these tumor cells which are very aggressive in vivo. 
 
In addition, the murine PDAC cells were also tested for nCIN both before and after 
inhibition of MPS1. 825-2 and 1170-4 cells were treated with 2.4 µmol/L and 2.7 µmol/L 
respectively for 72 hours after which they were analyzed by FISH. The concentrations of 
NMS-P715 used in this experiment were in calculated in accordance to their IC50 values 
of 1.3 and 2.2 µmol/L for 825-2 and 1170-4 respectively which was determined by 
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 Fig 18 Growth of murine PDAC was inhibited by NMS-P715 
A: Clonogenic survival assay. 825-2 and 1170-4 were seeded at a density of 100 and 50 
cells/well and treated with then indicated concentrations of NMS-P715 for either 5 days 
in a continuous treatment or for 24 for hours followed by growth in compound-free 
medium in washout treatment. Colonies that had at least 50 cells stained with giemsa 
were scored. 
B: On the left is a graph showing that nCIN in not elevated in murine PDAC cells after 
treating 825-2 and 1170-4 cells with 2.4 µmol/L and 2.7 µmol/L respectively for 72 
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hours. On the right is a representative image showing modal and non-modal number of 
chromosomes in the cells. The modal number of chromosome 11 was 7 for 825-2 and 4 
for 1170-4. 
  
 48   
 
Dr. Slee (Slee et al. 2014). The KRC cells did not show statistically significant elevation 
in nCIN after MPS1 was inhibited (Figure 18B). However, since KRC cells already 
display high nCIN with 65% and 45% modal deviation for a chromosome 11 probe in 
825-2 and 1170-4 in untreated cells they start with an extremely high basal nCIN rate. 
Cells with deleted Rb gene, which is the case in KRC cells, have been reported to be 
chromosomally unstable due to misregulation of MAD2 protein via E2F transcription 
factor (Manning, Longworth, and Dyson 2010). The very high basal nCIN rate in KRC 
cells prompted us to explore whether the SAC was compromised in KRC cells. KRC 
cells were treated with increasing concentration of nocodazole with the rationale that a 
weakened SAC will bypass the checkpoint and exit mitosis prematurely as they will not 
be blocked by nocodazole treatment. In this experiment, cells were plated at 10,000 to 
20,000 cells/well and treated with 25nmol/L, 50nmol/L and 75nmol/L nocodazole for 18 
hours. DMSO was used as control. The cells were then fixed in 4% formaldehyde and 
incubated with pS10H3 (green) antibody. The frequency of cells positive for pS10H3 
signals was calculated to test whether the cells were arrested in prometaphase when the 
microtubules were prevented from attaching to the kinetochore indicating the activation 
of SAC. There was no significant difference between the percentages of pS10H3 positive 
cells in control than those treated with nocodazole though the number of cells decreased 
with increasing concentration of nocodazole (Figure 19). However cells appeared to be 
less viable when incubated with nocodazole. This raises the possibility that the SAC is 
weak in KRC cells which reduced their viability as they try to go through an aberrant 
mitosis in the presence of nocodazole. This elevated sensitivity to nocodazole in cells 
with a weakened SAC is consistent with earlier published data (Sihn et al. 2003). Since 
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 Fig 19 Murine PDAC cells may have a weakened SAC 
Image shows murine PDAC cells arrested in prometaphase after 18 hour treatment with 
increasing concentrations of nocodazole as indicated. The percentage of cells positive for 
pS10H3 (green) is indicated below each panel. Nuclei appear blue due to staining with 
DAPI. The frequency of cells arrested in prometaphase in the treated cells was not 
significantly different than that observed in control (p>0.05; χ2 test). ≥200 cells were 
scored per well. The assay was performed in duplicate. 
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825-2 and 1170-4 cells already showed high basal nCIN in control treatment, increasing 
nCIN further may be lethal. 
 
In conclusion, the relative resistance towards NMS-P715 displayed by human ASCs and 
hTERT-HPNE normal pancreatic epithelial cells indicates that NMS-P715 may be 
selective towards pancreatic ductal adenocarcinoma cells while sparing stem cells. Mouse 
KRC PDAC cells, which are highly aggressive tumor cells in vivo, were also highly 
sensitive to NMS-P715 lending further support to the possibility that MPS1 inhibition 
may be a useful strategy for limiting growth of PDAC cells in vivo. 
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DISCUSSION 
 
1.  Thesis Summary 
 
Pancreatic ductal adenocarcinoma (PDAC) is the only major cancer with a 5 year 
survival rate in the single digits i.e. 6% (Siegel, Naishadham, and Jemal 2012, Hoos et al. 
2013). It is one of the commonly diagnosed cancers for which both the incidence and 
death rate is increasing (Hoos et al. 2013). Gemcitabine, which is the standard of care 
either alone or in combination with erlotinib or folfirinox (Sullivan and Kozuch 2012) 
can only provide a short increase in survival and has toxic effects (Choi, Saif, and Kim 
2014). This has warranted the development of therapeutics that target PDAC cells, that 
have improved efficacy and are less toxic to normal cells. 
 
The goal of this study was to exploit a vulnerability of PDAC cells. Like many tumors, 
PDAC tumors are chromosomally unstable, shows intra-tumor heterogeneity and up-
regulate MPS1 (Karhu, Mahlamaki, and Kallioniemi 2006, Gorunova et al. 1998, Slee et 
al. 2014). We demonstrate that PDAC cells are relatively more sensitive to MPS1 
inhibition than human adipose stem cells. 
 
Exploitation of a vulnerability in cancer cells has been traditionally linked to the 
existence of a pre-existing mutation followed by a second hit leading to cancer cell death. 
This has been successfully demonstrated in BRCA1 deficient tumors using PARP 
inhibitors (Fong et al. 2009). Here we build upon the hypotheses being proposed in the 
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literature that indicate that cancer cells become addicted to up-regulation of genes 
involved in chromosome segregation and that targeting them may lead to selective cancer 
cell death via massive chromosome mis-segregation (Colombo et al. 2010, Carter et al. 
2006, Yuan et al. 2006, Kwiatkowski et al. 2010, Lens, Voest, and Medema 2010, 
Sausville 2004). The antimitotic inhibitor of MPS1 kinase used in this study is modeled 
on the approach where selective increase of chromosomal instability may act as a second 
hit and push CIN beyond survivable limits leaving normal cells relatively unaffected 
(Colombo et al. 2010). Cancer cells, including pancreatic cancer cells and other solid 
tumors, up-regulate MPS1 and this up-regulation is proposed to keep nCIN within 
survivable limits (Carter et al. 2006, Yuan et al. 2006, Grabsch et al. 2003, Slee et al. 
2014). Inhibiting MPS1 kinase, a protein essential in the normal and equal segregation of 
chromosomes during mitosis, causes the abrogation of the spindle assembly checkpoint 
(SAC) followed by massive CIN and eventually cell death (Colombo et al. 2010, Kops, 
Foltz, and Cleveland 2004, Schmidt et al. 2005, Kwiatkowski et al. 2010). In previous 
studies, normal untransformed cells such as fibroblasts and B-lymphocytes remain 
largely unaffected by the NMS-P715 relative to breast cancer, colon cancer, renal 
carcinoma and melanoma cells (Colombo et al. 2010). Here, we tested the selective 
nature of MPS1 inhibition in normal human adipose stem cells (ASCs) as a model for 
how stem cells of the intestine or blood may be affected in vivo. The goal of my 
dissertation was to test the hypothesis that NMS-P715 can selectively kill PDAC cells in 
vitro by elevating mis-segregation of chromosomes while having much less effect on 
stem cells. Our in vitro MPS1 kinase inhibition assays in PDAC show promising results 
in selectively targeting pancreatic cancer cells by overriding the SAC and increasing 
 53   
 
chromosomal mis-segregation ultimately leading to cell death. This is consistent with the 
consequences of MPS1 inhibition observed over a range of cancer cell lines and 
xenograft models reported in previous studies (Colombo et al. 2010, Jelluma, Brenkman, 
McLeod, et al. 2008, Jelluma, Brenkman, van den Broek, et al. 2008, Kops, Foltz, and 
Cleveland 2004, Burds, Lutum, and Sorger 2005, Schmidt et al. 2005) and our studies 
demonstrate promise that MPS1 inhibition results in selective targeting of PDAC. 
 
2.  NMS-P715 selectively inhibits pancreatic cancer cell proliferation leaving 
human adipose stem cells relatively unaffected. 
 
In previous studies done by Dr. Slee in the Grimes lab, the half maximal inhibitory 
concentration value of the small-molecule inhibitor, NMS-P715, in ASCs is more than 
twice as that observed in the pancreatic cancer cells. In contrast, ASCs were highly 
sensitive to gemcitabine compared to PDAC cells (Slee et al. 2014). The differences 
between the growth of human ASCs and cancer cells was more pronounced in longer 
term clonogenic survival assays, when cells were either continuously treated for 3 days 
with 1.0 µmol/LNMS-P715 or exposed to a one day pre-treatment with NMS-P715. The 
inhibitor showed higher activity toward inhibition of proliferation of PANC-1 and BxPC-
3 PDAC cells while growth of ASCs was markedly less impacted. Growth of PDAC cells 
was inhibited when treated with 0.5 µmol/L NMS-P715 but ASCs showed only a 
marginal decrease in cell growth after treatment with the same concentration of the 
inhibitor. Being a long term assay to assess the proliferative capacity of cells after 
treatment, clonogenic survival assay takes into account all forms of cell death 
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mechanisms activated by the external insult to the cells as well as the heterogeneity 
within the population of cells with regards to the time of activation of the cell death 
machinery after treatment (Brown and Attardi 2005). The anti-proliferative results 
obtained in this study are in consistence with previous studies which showed that 
inhibition of essential mitotic checkpoint proteins such as MPS1 and BUBR1 causes 
death in cells within 6 cell divisions (Kops, Foltz, and Cleveland 2004). The new data 
presented here demonstrate that MPS1 inhibition results in significant growth impairment 
of PDAC cells while having less effect on ASCs thus opening up the possibility of a 
therapeutic window using MPS1 treatment to selectively target tumor growth in vivo. 
 
3. Selective override of the SAC in PDAC cells following MPS1 inhibition 
 
Our studies demonstrated that NMS-P715 abrogates the SAC in PDAC cells. 
Phosphorylation of Histone H3 at serine 10 (pS10H3) is a marker of cells in mitosis. 
Western analysis showed that PDAC cells exhibited a dose-dependent decrease in 
pS10H3 upon NMS-P715 treatment, reflecting premature exit from mitosis due to SAC 
over-ride whereas ASCs were unaffected under similar conditions. Furthermore NMS-
P715 treatment caused over-ride of a nocodazole block, again supporting the mechanism 
of SAC over-ride by NMS-P715. Finally our FISH analysis of cells treated with 1 µmol/L 
NMS-P715 was consistent with an increase in nCIN in PDAC cells while ASCs were not 
affected. These data, together with the comparative increase in cell growth inhibition of 
PDAC cells relative to ASCs supports our hypothesis that NMS-P715 treatment caused 
selective death to PDAC cells via massive CIN under conditions where stem cells are less 
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affected. The results in ASCs were further supported by NMS-P715 treatment of 
telomerase immortalized pancreatic ductal epithelial cells (hTERT-HPNE-1 cells). 
hTERT-HPNE cells also did not exhibit growth inhibition or elevated nCIN under 
conditions were PDAC cells exhibited increased nCIN and cell growth inhibition, again 
supporting the possibility of a therapeutic window where PDAC cells could be selectively 
targeted by MPS1 inhibition. These studies provide new insights into the mechanism of 
resistance of non-tumorigenic cells to MPS1 inhibition and suggest that the SAC is more 
resistant to override by MPS1 inhibition in stem cells and pancreatic epithelial cells than 
PDAC cells. The difference observed in differential sensitivity to MPS1 inhibition of 
tumorigenic versus non-tumorigenic cells could be related to 1) the increased basal levels 
of nCIN (as measured by the FISH assay) and 2) the relative up-regulation of MPS1 in 
PDAC cells. Current models suggest both that the increased level of CIN (both structural 
and numerical) make cancer cells particularly sensitive to increases in CIN (such as 
shown here by MPS1 inhibition and SAC abrogation) than normal cells, such as ASCs 
and hTERT-HPNE cells that are diploid (Grimes et al. 2009, Slee et al. 2014) as is 
evident from the data presented in this thesis. Furthermore, cancer cells may be addicted 
to up-regulation of MPS1 for their survival. The vulnerability of cancer cells to MPS1 
inhibition is discussed in further sections. 
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4. Murine PDAC cells show impaired growth when treated with NMS-P715 and 
may have a weakened SAC 
 
The anti-tumor activity of NMS-P715 was elevated in murine PDAC cells that were 
obtained from genetically engineered mice with oncogenic Kras and deleted Rb using 
cre-recombinase (KRC cells 825-2 and 1170-4) (Carriere et al. 2011). NMS-P715 
affected their proliferation in long-term clonogenic survival assays where the growth of 
825-2 & 1170-4 was completely abolished when treated continuously for 5 days with 
approx. 0.7 µmol/L inhibitor whereas their growth decreased by 85% after treatment with 
1.0 µmol/L for 24 hours. The KRC cells showed extreme CIN phenotype in the control 
group but did not show an increase in nCIN after treatment with their IC50 concentrations 
of the inhibitor for 72 hours. These data are consistent with previous reports where the 
inactivation of Rb gene is linked to CIN (Manning, Longworth, and Dyson 2010). 
Furthermore, the cells failed to arrest in prometaphase in the presence of nocodazole, a 
microtubule depolymerizing agent, indicating a weakened SAC (Sihn et al. 2003). As a 
result, the inhibition of MPS1 in murine PDAC cells may have completely abrogated the 
SAC making the treatment with NMS-P715 lethal to these cells (Kops, Foltz, and 
Cleveland 2004). 
 
Since in vitro results do not always mimic in vivo results, it will be interesting to see the 
anti-tumor effects of NMS-P715 in vivo by transplanting KRC cells in the pancreata of 
syngeneic immune competent mice. It has been observed that tumors in situ contain 
significantly lower percentage of dividing cells than in cell culture (Mitchison 2012) 
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which may affect the efficacy of the inhibitor in vivo since it only attacks mitotic cells. In 
addition, tumors are not only genetically heterogeneous but their microenvironments 
show variability as well (Orth et al. 2011) causing differential response within the tumor 
resulting in individual cells responding differently to the same compound (Yang et al. 
2010). Using syngeneic mice will allow the analysis of microenvironmental interactions, 
endocrine signaling tumor-secreting factors as well as effects of the immune system and 
vasculature on the tumor in response to the inhibitor (Pearson and Pouliot 2000). In 
addition, it will become possible to examine the impact of the inhibitor on the metastatic 
behavior of PDAC with the help of syngeneic mouse models (Pearson and Pouliot 2000). 
Testing these mice with NMS-P715 will give us a better understanding by taking into 
consideration factors such as cell-to-cell contact and hypoxia which are known to confer 
drug resistance in vivo (Sarasin 2003). 
 
5. Inhibition of MPS1 is selective towards PDAC cells in vitro whereas normal cells 
are less affected under similar conditions. 
 
To address the possibility that ASCs could not uptake small molecule inhibitors 
efficiently, an independent assay was conducted. The half minimal concentration (IC50) 
value of NMS-P715 for ASCs and hTERT-HPNE was 3.4 µmol/L indicating that the 
inhibitor did have an effect on cell growth though at a concentration much higher than 
that required for PANC-1 and BxPC-3 (Slee et al. 2014). In addition, ASCs showed 
statistically significant increase in nCIN after the cells were treated with 3 µmol/L 
inhibitor for 72 hours suggesting that the molecule was successful in inactivating the 
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SAC. These results indicate that the tumor cells lack the shield which normal cells 
possess in order to resist the inhibitory effects of NMS-P715. 
 
PDAC cells are aneuploid and display intra-tumor heterogeneity with respect to 
chromosome number as well as structure (Sirivatanauksorn et al. 2001) whereas ASCs 
maintain a diploid number (Grimes et al. 2009). In addition to other genetic and non-
genetic factors, mitosis in aneuploid cells is usually prolonged due to extra chromosomes 
that have to be attached to the spindle microtubules, aligned on the metaphase plate and 
segregated to the daughter cells (Yang et al. 2008). In addition, chromosomally unstable 
cells have more stable kinetochore-microtubule (KT-MT) attachments than normal cells 
due to massive variations in the expression of different spindle and kinetochore proteins 
in dividing tumor cells (Bakhoum, Genovese, and Compton 2009). The altered 
expression of these proteins also results in merotelic attachments of microtubules to the 
kinetochores which are usually undetected by the SAC resulting in lagging chromosomes 
during anaphase further triggering chromosomal mis-segregation (Bakhoum, Genovese, 
and Compton 2009). Inhibition of MPS1 is known to stabilize the already hyperstable 
KT-MT attachment (Kwiatkowski et al. 2010) thereby affecting segregation of 
chromosomes. 
 
Because normal cells differ from most tumor cells with respect to the number of 
chromosomes, stability of KT-MT attachments and balance of gene doses, MPS1 
inhibition can potentially be more selective towards PDAC cells. This increased 
sensitivity could be due to extensive genetic imbalances that the cancer cells had started 
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off with before treatment which make them unable to repair the damage and combat the 
stress that accompanied MPS1 inhibition (Kops, Weaver, and Cleveland 2005, Williams 
et al. 2008). Though our data demonstrates that NMS-P715 significantly affects ASCs at 
higher doses, the effect may be minimal and the affected cells may have been removed 
from the population as a result of selection towards diploid cells. However, the possibility 
of tumorigenic mutations in ASCs after treatment needs full considerations and will 
require further analysis of long term effects of the inhibitor on healthy cells. 
 
6. Future Directions 
 
The results of this study show great promise in selective killing of pancreatic cancer cells 
by inhibiting MPS1 kinase using a single-agent NMS-P715. However, in vivo analyses 
for anticancer drugs are necessary to understand the efficacy and delivery of the molecule 
in the target region of pancreatic cancer. This can be achieved by testing the inhibitor in 
orthotopic implantation of human PDAC cell lines in immunocompromised mice and 
also in syngeneic mouse models of pancreatic cancer as discussed earlier (Carriere et al. 
2011). Tumor microenvironment plays an important role in drug resistance, tumor 
recurrence as well as drug delivery (Olive et al. 2009). PDAC in mice, just as in human 
PDAC, is surrounded by a dense matrix that limits the blood supply to the malignant cells 
by compressing the vasculature thereby resulting in poor drug uptake and efficacy 
(Hingorani et al. 2003, Sofuni et al. 2005) making it necessary to study the inhibitor in 
vivo to improve its delivery to its site of action. It was earlier shown that MPS1 inhibition 
in xenograft mouse models for human ovarian carcinoma and melanoma impeded tumor 
 60   
 
growth (Colombo et al. 2010) and it now remains to be seen if these results are replicated 
in mouse models for PDAC as well. 
 
One of the biggest challenges in cancer therapeutics is tumors becoming drug-resistant. 
According to the National Cancer Institute, therapeutic resistance is a characteristic 
feature of PDAC (NCI 2014). Cancer cells become insensitive to therapeutic agents by 
different mechanisms such as accumulating mutations that enhance the cells’ survival, 
acidic microenvironment or limited blood supply to the tumor cells (Olive et al. 2009). 
SAC components are not mutated frequently but are instead overexpressed in 
chromosomally unstable tumors (Wang et al. 2004, Cahill et al. 1999, Carter et al. 2006, 
Yuan et al. 2006, Slee et al. 2014). However an unstable genome can give rise to new 
mutations that alter proteins and make them resistant to anti-cancer drugs. A study in 
2005 showed that a substitution mutation from methionine to glutamine in MPS1 kinase 
(M602Q) made the cells resistant to its inhibitor SP600125 thereby reducing its potency 
(Schmidt et al. 2005). This calls for testing the efficacy of NMS-P715 in PDAC cells in 
the event of an M602Q mutation or other similar alterations in the protein. 
 
To overcome the problem of drug-resistance, there has been more focus on designing 
combination therapies to improve patient outcomes. Various studies are being carried out 
to determine whether cancer cells can be sensitized to MPS1 inhibition by combination 
with compounds targeting other mechanisms critical for cells survival pathways that 
rescue cells from proteotoxic stress and proteins involved in DNA damage response 
(Torres et al. 2007, Janssen, Kops, and Medema 2009). It has been previously shown that 
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reducing the levels of MPS1 increased the sensitivity of tumor cells to low doses of 
paclitaxel, a microtubule destabilizing agent, resulting in synergistic lethality of the 
treated cells. (Janssen, Kops, and Medema 2009). Interestingly, both nab-paclitaxel 
(Frese et al. 2012) or IPI-926, the inhibitor of the Hedgehog signaling pathway (Olive et 
al. 2009), are individually shown to improve the delivery of gemcitabine in PDAC in 
mice which may also improve NMS-P715 delivery to tumors in future studies. Enhancing 
multipolar division by preventing clustering of chromosomes along with MPS1 inhibition 
is also known to be a promising strategy in dramatically reducing the viability of PDAC 
tumor cells (Kwon et al. 2008, Janssen and Medema 2011). Furthermore, the ability to 
selectively reduce chromosomally unstable cells within the tumor may give agents 
targeting pathways altered in patient sub-populations more chance of working as tumor 
heterogeneity that is thought to promote drug resistance would be suppressed due to 
MPS1 inhibition. 
 
To ensure clinical success of NMS-P715 in the treatment of PDAC, a long term endpoint 
in clinical trials is needed to determine whether MPS1 inhibition could promote cancer in 
healthy cells if, at a very low level, CIN is increased through a minor effect on the SAC. 
As with any drug, it will be necessary to study whether NMS-P715 shows good tumor 
penetration and efficacy and exhibit toxicity within acceptable limits. At least in 
xenografts for ovarian cancer and malignant melanoma, NMS-P715 showed good 
efficacy and target engagement and no overt toxicities were reported (Colombo et al. 
2010). Interestingly, a derivative potent and selective MPS1 kinase inhibitor developed 
by Nerviano Medical Sciences will soon enter Phase I clinical trials in triple-negative 
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breast cancer (TNBC) patients (NMS 2013) which lack over-expression of human 
epidermal growth factor 2 (HER2) and absence or reduced expression of progesterone 
estrogen receptors. TNBC cells are also the most chromosomally unstable subset of 
breast cancers (Smid et al. 2011, Foulkes, Smith, and Reis-Filho 2010). It will be 
interesting to follow the results of these clinical trials in the hope that they will yield 
positive results without serious side effects and their subsequent testing in other tumor 
types, including pancreatic cancer. 
 
7. Concluding Remarks 
 
The data presented in this study lead us to conclude that the abrogation of the SAC by 
inhibiting MPS1 kinase is a potentially novel approach to pancreatic cancer therapy 
because it selectively blocks the proliferation of pancreatic tumor cells while leaving 
normal stem cells relatively unaffected. Our results suggest a favorable therapeutic 
window of the MPS1 inhibitor and warrant development of pre-clinical models for testing 
the capacity of NMS-P715 to selectively target primary and metastatic PDAC tumors. 
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Indiana University School of Medicine, Indianapolis, IN 
• Investigated the effects of a small molecule chemotherapeutic drug, mitotic kinase 
MPS1 inhibitor, on normal human adipose stem cells in comparison with pancreatic 
cancer cells by performing long and short term proliferation assays as well as 
techniques such as Western Blot, Immunocytochemistry and Fluorescence in situ 
hybridization 
• Assessed micronuclei formation in cultured human cells as an indirect measurement 
of chromosomal instability 
• Maintained the growth of human and mice tumor and non-tumor cell lines such as 
pancreatic ductal adenocarcinoma cells, telomerase-immortalized pancreatic ductal 
epithelial cells, fibrosarcoma cells and adipose stem cells 
 
Cytogenetic Laboratory Experience 1/2013 – 5/2013 
Cytogenetic Division, 
Indiana University School of Medicine, Indianapolis, IN 
Performed techniques such as karyotyping and multicolor fluorescence in situ 
hybridization (M-FISH) analysis to detect and analyze chromosomal abnormalities in 
cytogenetic disorders 
 
 
 
 
Undergraduate Independent Study Research Experience 7/2010 – 2/2011 
Fergusson College, 
University of Pune, Pune, India 
Analyzed the effects of waste water from different industrial lines in promoting the errors 
in stages of mitosis in Allium cepa root tips and on anatomic malformations in the 
development of early chick embryos 
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• Bansal R, Blackburn C, Brown L, Gasaway R, Victorino J, Jeong J, Gore J, March 
KL , Herbert BS, Colombo R, Korc M, Slee RB and Grimes BR. An inhibitor of the 
mitotic kinase, MPS1, is selective towards pancreatic cancer cells. (2014). 5th Annual 
Midwest Graduate Research Symposium. March 29. University of Toledo, Toledo, 
Ohio, USA 
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KL , Herbert BS, Colombo R, Korc M, Slee RB and Grimes BR. An inhibitor of the 
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STEM Research Poster Session sponsored by IUPUI Women in Science. March 6. 
Indiana University Purdue University at Indianapolis, Indianapolis, Indiana, USA 
• Bansal R, Blackburn C, Brown L, Gasaway R, Victorino J, Jeong J, Gore J, March 
KL , Herbert BS, Colombo R, Korc M, Slee RB and Grimes BR. An inhibitor of the 
mitotic kinase, MPS1, is selective towards pancreatic cancer cells. (September 2013) 
Department of Medical and Molecular Genetics Poster Session. September 17. 
Indiana University School of Medicine, Indianapolis, Indiana, USA 
• Victorino J, Slee RB, Bansal R, Korc M, Grimes BR. Targeting Chromosome 
Instability (CIN) in pancreatic cancer. (2013) Bridges to the Doctorate Program 
Summer Poster Session. July 25-26. Indiana University Purdue University at 
Indianapolis, Indianapolis, Indiana, USA 
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(2013) Cancer Research Day. May 22. Indiana University School of Medicine, 
Indianapolis, Indiana, USA 
• Blackburn C, Slee RB, Bansal R, Brown L, March KL, Herbert BS, Korc M, Grimes 
BR. The Mitotic Kinase, MPS1, as a Therapeutic Target in Pancreatic Cancer. (2013). 
Indiana University Life Health Sciences Internship Program Poster Session. April 12. 
Indiana University School of Medicine, Indianapolis, Indiana, USA. 
• Brown L, Slee RB, Bansal R, Blackburn C, March KL, Herbert BS, Korc M, Grimes 
BR. (2013). Human Adipose Stem Cells are more Resistant than Pancreatic Cancer 
Cells to NMS-P715, a Mitotic MPS1 Kinase Inhibitor. Indiana University Life Health 
Sciences Internship Program Poster Session. April 12. Indiana University School of 
Medicine, Indianapolis, Indiana, USA 
 
Awards 
 
Poster Presentation Award March 2014 
Third prize in Graduate Division 
Women in STEM Research Poster Session, IUPUI, Indianapolis, IN 
 
Campus and community involvement 
 
• Volunteer Laboratory Assistant for Human Tissue Collection 1/2013 – 11/2014 
Event 
Susan G. Komen for the Cure Tissue Bank, 
Indiana University Simon Cancer Center, Indianapolis, IN 
• International Graduate Welcome Volunteer 7/2013 – 5/2014 
Indiana University Purdue University, Indianapolis, IN 
• Chromosome Research Group 3/3013 – 5/2014 
Indiana University School of Medicine, Indianapolis, IN 
• Class Coordinator 11/2008 – 1/2009 
Fergusson College, Pune, India 
Represented the First Year Class of Bachelor of Science program in Biotechnology 
for the annual departmental festival, ‘Chimera’ 
